CAR T-cell reprogramming is a critical strategy for treating prostate cancer because it addresses the major biological barriers that have historically made this “immunologically cold” tumor resistant to standard CAR T therapies. While CAR T-cell therapy has excelled in blood cancers (yet another recent publication, the full version here), its success in prostate cancer depends on “reprogramming” the cells to survive and function within a highly hostile and suppressive environment.
What is CAR T-cell reprogramming, what can I learn from it, and what can I do with what I am learning?
What is CAR T-cell reprogramming?
CAR-T cell reprogramming (Chimeric Antigen Receptor T-cell therapy) is a personalized immunotherapy that genetically modifies a patient’s own T-cells to better recognize and destroy cancer cells. It involves extracting immune cells, engineering them to produce special receptors (CARs), growing them in a lab, and reinfusing them to fight blood cancers like lymphomas and leukemias.
Key Aspects of CAR-T Cell Reprogramming:
- Extraction: Doctors collect a patient’s T-cells through a process called leukapheresis.
- Genetic Engineering: In a laboratory, a new gene is introduced into the T-cells, enabling them to produce a “chimeric antigen receptor” (CAR) on their surface.
- Targeting Abilities: This modification allows the T-cells to specifically identify and attack proteins found on cancer cells that they previously failed to recognize.
- Expansion: Millions of these reprogrammed cells are grown in the lab to ensure a strong therapeutic dose.
- Infusion and Action: The cells are reinfused into the patient, where they multiply and attack the cancer.
- Primary Uses: It is mainly used for relapsed or refractory blood cancers, including Acute Lymphocytic Leukemia (ALL), Diffuse Large B-cell Lymphoma, and Multiple Myeloma.
Why Reprogramming Is Essential for PCa
Traditional CAR T-cells often fail in fighing PCa due to three primary obstacles that reprogramming is designed to overcome:
Immunosuppressive Microenvironment (TME): Prostate tumors are rich in TGF-β, a signaling molecule that shuts down T-cell activity. Reprogramming cells to be TGF-β-insensitive (by adding a dominant-negative receptor) has shown in trials to significantly improve T-cell proliferation and tumor control.
T-Cell Exhaustion: The harsh conditions within solid tumors quickly “exhaust” T cells, making them inactive. Genetic reprogramming, such as PD-1 disruption via CRISPR/Cas9, helps the cells maintain their killing power for longer periods.
Physical and Metabolic Barriers: Reprogramming can include “arming” the cells with cytokines (e.g., IL-12, IL-15) or chemokine receptors (e.g., CXCR4) to help them physically penetrate the dense tumor stroma and home in on metastatic sites, such as bone lesions.
Current Reprogramming Strategies in Trials
Research is moving toward fourth-generation “armored” CAR T cells and other advanced designs specifically for metastatic castration-resistant prostate cancer (mCRPC):
Antigen Specificity: Targeting markers like PSMA (Prostate-Specific Membrane Antigen) and PSCA (Prostate Stem Cell Antigen).
Dual Targeting: Reprogramming cells to recognize two antigens at once to prevent “antigen escape,” where cancer cells stop expressing one target to avoid detection.
Logic-Gated CARs: Creating “AND-gated” circuits where the T cell only activates if it detects two specific markers, which protects healthy tissues and reduces side effects like cystitis (bladder inflammation).
Metabolic Priming: Adjusting the cells’ internal metabolism during manufacturing to ensure they can survive in the nutrient-depleted and low-oxygen environment of a tumor.
Key Clinical Results
Early Phase I trials (e.g., using P-PSMA-101) have demonstrated safety and transient PSA declines of over 30–50% in subsets of patients.
Combining reprogrammed CAR T-cells with low-dose chemotherapy (lymphodepletion) has been shown to “boost” their effectiveness by clearing out competing immune cells.
What can I take away from all of this?
My research-based Diet, Excercise, and Supplements approach to fighting my PCa uses epigenetic techniques which are less drastic and apparently less risky than fully-blown Genetic Engineering approaches such as CRISPR or mRNA vaccines. Epigenetic approaches create changes in organisms caused by modification of gene expression rather than alteration of the genetic code itself. This means that the foods and supplements I put into my body alters they way the existing DNA acts, either activating biological sequences previous dormant, or suppressing other biological sequences previously inactive. The DNA itself is left unaltered, it just behaves differently. CRISPR on the other hand, actually alters DNA.
And epigenetics is something I can do myself at home. Finding the Holy Grail during my PCa journey involves a complete shutdown of PCa cellular activity. Research shows that PCa cellular activity has been either completely or drastically shut down in in-vitro environments, that is outside the body where my epigenetic methods are extremely effective. For example, ingesting Pomegranate Seed Oil (PSO) floods the body with Punicic Acid. In-vitro application of Punicic Acid in the range of 10 to 100 uM/L killed all 5 metastatic lines of research PCa.
But trying to reproduce this bloodstream concentration in-vivo ( inside the body) remains the challenge for me. Its one thing to put a drop of Punicic Acid on PCa cells in a petri dish, and another thing to ingest PSO and have it get digested in the stomach and intestines before it’s absorbed into the blood stream and can travel to wherever the PCa cells are. I can’t help thinking the answer to delivering higher concentrations lies in the unique delivery systems that are currently being invented for use in CRISPR and mRNA-vaccine style therapies.
But is sure does seem like I am getting results. My PSA dropped in half, from 6 to 3. My second MRI and biopsy indicated that my PIRADS 4, 1.4cm lesion was no longer well-organized. This means what I am doing may have broken down the Tumor Microenvironment (TME) giving my immune cells greater access to fighting my PCa. The tumor microenvironment (TME) is the complex ecosystem surrounding a tumor, comprising cancer cells, stromal cells (fibroblasts, endothelial cells), immune cells, and the extracellular matrix (ECM). It acts as a critical niche that supports tumor growth, enables immune evasion, promotes metastasis, and creates resistance to therapies like chemotherapy and immunotherapy. Is this why my PSA dropped? It’s also reassuring that no matter if tiny amounts of PCa may migrate, my blood travels everywhere and can fight it wherever it finds it. Traditional radiation and surgery are only locally effective by design. And for whatever reason, my approach, using diet and supplements, has shown to be much safer, with fewer side effects.
Best of Science for Everyone !
Leave a Reply